1. Union Chimique Belge

2. Overview
• What is UCB?
• Financial Analysis
• Outlook 2012
• Conclusion
• Sources

3. UCB ?
• Multinational
• Biopharmaceutical Manufactoring Company
• Medication ( Epilepsy, Parkinson and Crohn’s
diseases.)

4. Financial Analysis

5. Revenue
4000
3626 3601
3500 3188
3027 3116 3218 3246
3000
2683 2786 2876
2500
Million €
2000
1500 net sales
1000 Revenu
500
0
2007
2008
2009
2010
2011
year

6. Net sales 2011 by region
18%
49% Europe
North America
Rest of the World
33%

7. Net sales 2011 by product

8. Net profit
600
500 513
400
Million €
300
235
200
160
100 103
42
0
2007 2008 2009 2010 2011
year

9. € billion 2007 2008 2009 2010 2011
Market 5.7 4.3 5.3 4.7 5.9
capitalisation
(year-end)
€ 2007 2008 2009 2010 2011
Earnings per 0.89 0.24 2.85 0.57 1.32
share
High of the year 54.10 25.90 31.50 33.60 34.10
Low of the year 30.30 21.30 19.17 22.50 25.60
Year-end 31.02 23.30 29.22 25.67 32.51
share price
Average daily 685 893 452 632 382 566 313 756 257 478
trading volume
N° of shares 183 361 252 183 365 052 183 365 052 183 365 052 183 365 052
outstanding
(year-end)

10. Outlook 2012
• Revenu  3,2 billion euro  = 2011
• Net Profit  196 million euro  2011
• Continued growth of Cimzia, Vimpat, Neupro and
Keppra

11. Conclusion
• Worldwide
• Financially strong company
• innovative

12. Thank you for
your attention!

13. Sources
• http://www.ucb.com/investors/financials/key-data
• http://www.ucb.com/investors/shares
• http://www.ucb.com/investors/financials/outlook
• http://www.ucb.com/investors/financials/analyst-
consensus
• http://2011.ucb-annual-report.com/home